Song, S., Xie, M., Scott, A.W., Jin, J., Ma, L., Dong, X., et al. (2018) A Novel YAP1 Inhibitor Targets Csc-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma. Molecular Cancer Therapeutics, 17, 443-454.
https://doi.org/10.1158/1535-7163.mct-17-0560

has been cited by the following article:

• TITLE: The Regulatory Mechanism and Therapeutic Targets of the HIPPO Pathway in Helicobacter pylori-Associated Gastric Cancer

  AUTHORS: Hao Tan, Ping Lu

  KEYWORDS: Helicobacter pylori, Gastric Cancer, HIPPO Pathway, YAP/TAZ, CagA

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.9, September 3, 2025

  ABSTRACT: The HIPPO signaling pathway critically regulates cell proliferation, apoptosis, and tissue homeostasis, playing a pivotal role in Helicobacter pylori (H. pylori)-associated gastric cancer, a major contributor to the global gastric cancer burden. Dysregulation of HIPPO signaling, particularly through YAP/TAZ activation, drives tumorigenesis, invasion, and metastasis in H. pylori-infected gastric tissues. This review elucidates the molecular mechanisms by which H. pylori virulence factors, such as CagA, disrupt HIPPO pathway components, including MST1/2 and LATS1/2 kinases, and explores epigenetic and pathway crosstalk mechanisms. We also discuss promising therapeutic targets, including YAP/TAZ inhibitors and combination strategies with H. pylori eradication therapies. These insights aim to guide the development of targeted interventions for H. pylori-related gastric malignancies.